Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Registration Number
- NCT04761978
- Lead Sponsor
- University Hospital, Lille
- Brief Summary
The aim is to assess effectiveness (EASI, SCORAD, IGA, DLQI, pruritus, sleep loss) and safety (clinical and biological adverse events) of JAK inhibitors in adults with moderate-to-severe atopic dermatitis in a real-life French multicenter retrospective cohort
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
- Adults
- moderate to severe atopic dermatitis
- treated by JAK inhibitors between december 2020 and september 2021
- inefficiency, loss of efficiency or contra-indication of previous systemic agent, DUPILUMAB or phototherapy
- ineligibility to French ongoing clinical trials
Exclusion Criteria
- Children
- mild atopic dermatitis
- eligibility to CICLOSPORINE, METHOTREXATE, DUPILUMAB, phototherapy
- eligibility to French ongoing clinical trials
- patients' opposition for the use of their records
- follow up <3 months
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method reduction in Eczema Area and Severity Index (EASI) At 3 months
- Secondary Outcome Measures
Name Time Method Dermatology Life Quality Index (DLQI) at baseline and at 3 months patient-reported sleep loss from 0 to 10 at baseline and at 3 months Adverse effects (biological and clinical) at baseline and at 3 month patient-reported pruritus score from 0 to 10 at baseline and at 3 months SCORing Atopic Dermatitis (SCORAD) at baseline and at 3 months Investigator's Global Assessment (IGA) at baseline and at 3 months
Trial Locations
- Locations (1)
Hop Claude Huriez Chu Lille
🇫🇷Lisle-sur-Tarn, France